Targeting Anhedonia in Cocaine Use Disorder

Phase 2

Completed

• Conditions: Cocaine-Related Disorders; Anhedonia
• Interventions: Drug: d-amphetamine; Behavioral: Contingency management; Drug: Placebo (for d-amphetamine)

• Registration Number: NCT02773212
• Lead Sponsor: University of Illinois at Chicago

Brief Summary

The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adjunctive treatment with a dopaminergic (DAergic) drug, d-amphetamine, on outcomes in CM for CUD, as well as investigate the contribution of anhedonia to overall CUD severity.

Detailed Description

Recent research suggests that anhedonia is a key neurobehavioral dysfunction in Cocaine Use Disorder (CUD) that contributes to treatment outcomes. Anhedonia, defined here as lack of interest or pleasure in non-drug rewards, is frequently found in CUD and is related to neural deficits, such as low striatal dopamine and deficient activation to non-drug rewards in mesocortical circuits. Interestingly, not all individuals in CUD have these deficits. Preliminary data suggests that the presence of self-reported anhedonia predicts worse outcome in contingency management (CM) treatment of CUD. Moreover, low baseline dopamine predicts failure to attain abstinence in CM while medications that enhance DA increase CM success rates and responsiveness to rewards.

This study specifically aims to test the contribution of anhedonia to overall CUD severity, the relationship of anhedonia to outcomes in CM treatment, and the mediating role of anhedonia in medication enhancement of CM in CUD. To accomplish these aims, individuals with CUD will be enrolled and will undergo 4 weeks of intensive CM treatment, either with or without treatment with the dopaminergic drug, d-amphetamine. A medication only group will be included to solely measure the effects of d-amphetamine. Anhedonia will be assessed using multi-modal subjective, psychophysiological and behavioral measures of reward functioning at baseline, and each week of treatment. Functional magnetic resonance imaging (fMRI) measures of reward functioning will also be taken at baseline and week 4 in a subset of participants (n = 24)

Study Timeline

• Study First Submitted: 2016-05-06
• Study First Submitted QC: 2016-05-11
• Study First Posted: 2016-05-16
• Study Start: 2017-02-01
• Primary Completion: 2022-04-04
• Study Completion: 2022-04-04
• Results First Submitted: 2024-06-04
• Status Verified: 2024-08
• Results First Submitted QC: 2024-08-01
• Last Update Submitted: 2024-08-01
• Results First Posted: 2024-08-09
• Last Update Posted: 2024-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• be between 18 and 60 years of age
• meet Diagnostic and Statistical Manual V (DSM-5) criteria for current cocaine use disorder of at least moderate severity (≥ 4 symptoms)
• have at least 1 cocaine positive urine sample during the baseline screening period
• be in acceptable health on the basis of interview, medical history and physical exam, per the judgment of our study physician
• be able to understand the consent form and provide written informed consent
• be able to provide the names of at least 2 persons who can generally locate their whereabouts.
• if female, agree to use an acceptable method of birth control during study (surgical sterilization, approved hormonal contraceptives, barrier methods with spermicide, or intrauterine device).

Read More

Exclusion Criteria

• current DSM-5 diagnosis for substance use disorder of least moderate severity (≥ 4 symptoms), other than cocaine, nicotine, marijuana, or alcohol
• Physical dependence on alcohol requiring medically supervised detoxification, in the judgment of the study physician
• current amphetamine use (by self-report in past 30 days or positive urine drug screen), more than 50 lifetime uses of amphetamine, or history of DSM-5 Amphetamine Use Disorder
• a current DSM-5 axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe
• significant current suicidal or homicidal ideation
• medical conditions contraindicating d-amphetamine (e.g., significant cardiovascular disease, liver or kidney disease, seizure disorder, hypotension or hypertension)
• taking medications known to have effects on the central nervous system or that could cause significant drug interactions with d-amphetamine (e.g., clonidine, prazosin)
• having conditions of probation or parole requiring reports of drug use to officers of the court
• impending incarceration
• pregnant or nursing for female patients
• inability to read, write, or speak English

Additional Exclusion Criteria for the functional magnetic resonance (fMRI) Sub-Study (in addition to all listed criteria above for the Main Treatment Study):

• body mass index (BMI) >30, as this may be incompatible with the magnetic resonance scanner gantry
• any retained metals in the body, including implants and metallic substances (e.g. aneurysm clips, retained metal particles in metal workers, magnetic dental implants, ferromagnetic ocular implants, iron-based facial tattoos), as this may cause adverse effects to participants and interfere with data collection in the MR magnetic field
• inability to tolerate small, enclosed spaces (such as the magnetic resonance scanner bore)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
d-Amphetamine and Contingency Management	Contingency management	Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
Placebo and Contingency Management	Contingency management	Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
Placebo and Contingency Management	Placebo (for d-amphetamine)	Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
d-Amphetamine and Contingency Management	d-amphetamine	Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
d-Amphetamine alone	d-amphetamine	Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.

Primary Outcome Measures

Name	Time	Method
Number of Participants Who Were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy)	At end of active treatment (Treatment week 4)	Subjects will complete a urine drug screen each visit. Achievement of cocaine abstinence will be defined as two consecutive weeks of cocaine-negative urine samples.

Secondary Outcome Measures

Name	Time	Method
Cocaine Negative Urine Samples	At end of active treatment (Treatment week 4)	Subjects will complete a urine drug screen each visit (3x weekly). The Treatment Effectiveness Score is defined as the total number of cocaine negative urines across the 4 weeks of treatment (possible total of 12).

Trial Locations

Locations (1)

University of Illinois at Chicago; 🇺🇸 Chicago, Illinois, United States